Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
about
Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosisLung infections associated with cystic fibrosis.Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA)Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.A quadruple knockout of lasIR and rhlIR of Pseudomonas aeruginosa PAO1 that retains wild-type twitching motility has equivalent infectivity and persistence to PAO1 in a mouse model of lung infectionSerum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosisPrediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assayProspective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.Antibody response of fibrocystic patients to homologous 0-typable and 0-defective isolates of Pseudomonas aeruginosa.Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.Amount, avidity, and specificity of antibodies to Pseudomonas aeruginosa in normal human sera.Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis.Elevated IgG4 serum levels in patients with cystic fibrosis.Pseudomonas infections in cystic fibrosis.An immunoproteomic approach for identification of clinical biomarkers for monitoring disease: application to cystic fibrosis.Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.
P2860
Q24202023-5DD704F7-77AA-4255-877E-6A71D36CC9D9Q30080000-EBF00C9A-BB78-4754-A8CA-709580A2A5E8Q34076289-46044032-DC22-4799-9C81-19C789DF3737Q34278502-6A992682-B5F6-411A-B3C6-760B93C00A4CQ34424777-8B4F5FB3-CE28-431A-B35F-39192ED7FB74Q34674408-8FDE9319-BEE8-4240-9689-E2F28BF20BE1Q35603718-74D1473A-B302-413E-A8A0-CAD35CBEFDBCQ35625095-D0E74BEE-A419-4EE2-8161-E24EB40CEDCDQ35627870-AFE643A8-9F97-41DF-971D-2C19DD0D1C5BQ37152896-CFA0033D-A669-4320-BF7F-6D2E15D9B6D8Q37174632-C7E6CE08-DBB8-4E72-AEDC-25E3C3BDFDC3Q37220029-5369E1A5-C045-4018-8C97-51CBBA69F9D8Q37220313-55C11087-1001-4D64-8D84-746264BBF06CQ37260980-F94511D8-F103-4F88-A752-46CA28CECDCFQ39859766-7F056E7B-C718-4D28-A036-B7BCF514688CQ40199797-B9607054-F198-4894-9647-BAD3F6A69117Q40982307-DF547D03-66EC-4F15-99DA-2F9CFD16AF62Q41702615-FDBF099A-8D9F-4E15-9EE7-6C128B04D003Q41819894-9D87557B-D6AD-44DE-A5BD-BA2EF826AC7DQ46497247-2DDC534A-30CD-4876-9275-A2EF7D7786E4Q53297625-AAF29139-78D4-45FE-A5AB-349CA000F273
P2860
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@ast
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@en
type
label
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@ast
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@en
prefLabel
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@ast
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@en
P2093
P2860
P921
P356
P1476
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.
@en
P2093
Ghoneim AT
Littlewood JM
P2860
P304
P356
10.1136/ADC.61.11.1114
P407
P577
1986-11-01T00:00:00Z